S
Stuart W. Bright
Researcher at Eli Lilly and Company
Publications - 15
Citations - 707
Stuart W. Bright is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Monoclonal antibody & Antibody. The author has an hindex of 7, co-authored 15 publications receiving 678 citations.
Papers
More filters
Journal ArticleDOI
FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho.
Alexei Kharitonenkov,James D. Dunbar,Holly A. Bina,Stuart W. Bright,Julie S. Moyers,Chen Zhang,Liyun Ding,Radmila Micanovic,Sean F. Mehrbod,Michael D. Knierman,John E. Hale,Tamer Coskun,Armen B. Shanafelt +12 more
TL;DR: Results indicate that βKlotho and FGFRs form the cognate FGF‐21 receptor complex, mediating F GF‐21 cellular specificity and physiological effects.
Journal ArticleDOI
Association of intestinal peptide transport with a protein related to the cadherin superfamily.
Anne H. Dantzig,JoAnn Hoskins,Linda B. Tabas,Stuart W. Bright,Robert L. Shepard,Ivan L. Jenkins,Dale C. Duckworth,J. Richard Sportsman,Daniel Mackensen,Paul Robert Rosteck,Paul L. Skatrud +10 more
TL;DR: A monoclonal antibody that blocked uptake of cephalexin was used to identify and clone a gene that encodes an approximately 92-kilodalton membrane protein that was associated with the acquisition of peptide transport activity by transport-deficient cells.
Journal ArticleDOI
Design of Signal Windows in High Throughput Screening Assays for Drug Discovery
G. Sitta Sittampalam,Philip W. Iversen,Joyce A. Boadt,Steven D. Kahl,Stuart W. Bright,Joseph Martin Zock,William P. Janzen,Mark D. Lister +7 more
TL;DR: This work introduces the idea of a signal window which provides a degree of separation between signals which allows one to correctly identify new molecular entities with desired level of activity in the presence of variability.
Patent
Anti-il-23 antibodies.
Catherine Brautigam Beidler,Stuart W. Bright,Craig Duane Dickinson,Kristine Kay Kikly,David Matthew Marquis,Alain Philippe Vasserot +5 more
TL;DR: In this article, isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23 were presented, which are high affinity, neutralizing antibodies useful for the treatment of autoimmune disease.
Journal ArticleDOI
Competitive particle concentration fluorescence immunoassays for measuring anti-diabetic drug levels in mouse plasma
Stuart W. Bright,Frank C. Tinsley,Samuel J. Dominianni,Schmiegel Klaus K,Lora Louise Fitch,Gerald Gold +5 more
TL;DR: Two competitive particle concentration fluorescence immunoassays were developed to measure blood levels of analogs of anti-diabetic drugs being tested in diabetic mice and noted crossreactivity of one monoclonal antibody for 3 different compound classes that are all known to bind with varying affinities to peroxisome proliferator-activated receptors.